Regarding the UPR, the IRE1α-XBP1s branch was activated in ~18% of AML patients, as suggested by the increased expression levels of the spliced variant of XBP1, of GRP78, and of calreticulin (Figure 2) [97,98,99]. This evidence concerns the gene XBP1 and acute myeloid leukemia.